Bernstein analyst William Pickering maintains $Regeneron Pharmaceuticals (REGN.US)$ with a buy rating, and adjusts the target price from $1,210 to $1,110.
According to TipRanks data, the analyst has a success rate of 58.8% and a total average return of 4.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
Regeneron's third-quarter results surpassed expectations on revenue and more significantly in EPS. However, the performance of the Eylea franchise was a predominant concern. The impending introduction of a biosimilar version of Eylea's standard dose by a competitor casts doubt on the future of the franchise. This includes the potential underappreciated rate of erosion for the standard dose and possible impact on the high dose variant.
The recent decline in Regeneron's share value is viewed as an excessive response to the latest developments concerning Pavblu, the less than favorable projections for Q4 Eylea HD, and the absence of clear communication regarding future growth prospects for Eylea.
The recent decline in Regeneron's stock post-Q3 earnings took many by surprise, as it was thought that the near- and long-term consensus estimates for the ophthalmology franchise were overly optimistic. Despite this, it is believed that the intrinsic value of Regeneron's fundamentals remains significantly higher than the current share price.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
聯博集團分析師William Pickering維持$再生元製藥公司 (REGN.US)$買入評級，並將目標價從1,210美元下調至1,110美元。
根據TipRanks數據顯示，該分析師近一年總勝率為58.8%，總平均回報率為4.2%。
此外，綜合報道，$再生元製藥公司 (REGN.US)$近期主要分析師觀點如下：
雷根納第三季度的業績超過了預期的營業收入和更重要的每股收益。然而，艾利雅子公司的表現是一個主要的關注點。競爭對手即將推出艾利雅標準劑量的生物類似物版本，對該子公司的未來蒙上了一層陰影。這包括標準劑量可能被低估的侵蝕速率，以及對高劑量變種可能產生的影響。
對雷根納股價最近的下跌被視爲對Pavblu最新動態、對Q4艾利雅HD的預期不佳以及對未來艾利雅增長前景缺乏明確溝通的過度反應。
雷根納股價在第三季度業績後大幅下降讓許多人感到意外，人們認爲眼科醫療子公司的近期和長期共識預測過於樂觀。儘管如此，人們認爲雷根納基本面的內在價值仍然顯著高於當前股價。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
